These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 982342)

  • 1. Results obtained with prodectin in arteriosclerotic arterial obliteration of the lower extremities.
    Hunyi L
    Ther Hung; 1976; 24(2):67-71. PubMed ID: 982342
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of conservative (Prodectin) treatment and surgical intervention in arteriosclerotic obliterative diseases of the lower extremities.
    Hunyi L
    Ther Hung; 1978; 26(2):77-80. PubMed ID: 684660
    [No Abstract]   [Full Text] [Related]  

  • 3. [Treatment of arteriosclerotic peripheral chronic obliterating arteriopathies (A.P.C.O.) of the lower extremities with a new pharmacologic combination].
    Bagliani A; Borri P; Parravicini R
    Minerva Cardioangiol; 1975 Nov; 23(11):701-10. PubMed ID: 1223674
    [No Abstract]   [Full Text] [Related]  

  • 4. [Late results of the pyridinolcarbamate treatment of thrombotic obliterating arterial diseases of the extremities].
    Fisanovich TI; Tolstova LG
    Khirurgiia (Mosk); 1979 Sep; (9):76-80. PubMed ID: 502312
    [No Abstract]   [Full Text] [Related]  

  • 5. The effect of Prodectin (pyridinolcarbamate) treatment of the circulation rate in obliterating arterial diseases of the lower extremities.
    Fényes G; Gótzy G; Fehrentheil L
    Ther Hung; 1975; 23(2):64-66. PubMed ID: 1188705
    [No Abstract]   [Full Text] [Related]  

  • 6. [Clinical evaluation of pyridinolcarbamate effect on patients with obliterating atherosclerosis (author's transl)].
    Roztocil K; Oliva I; Linhart J; Prerovský I; Modr Z
    Cas Lek Cesk; 1976 Aug; 115(33-34):1051-5. PubMed ID: 975177
    [No Abstract]   [Full Text] [Related]  

  • 7. The effect of pyridinolcarbamate after acute and chronic administration in patients with atherosclerosis obliterans.
    Roztocil K; Oliva J; Linhart J; Prerovský I; Modr Z
    Int J Clin Pharmacol Biopharm; 1977 Mar; 15(3):135-8. PubMed ID: 844932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of prodectin in the treatment of cerebral arteriosclerosis and its complications.
    Abrányi I; Máté
    Ther Hung; 1976; 24(1):20-3. PubMed ID: 790631
    [No Abstract]   [Full Text] [Related]  

  • 9. [Therapeutic efficacy of pyridinolcarbamate (Anginin) in patients with combined cerebral and peripheral arteriosclerosis].
    Majkowski J; Lysakowska-Sernicka K; Gajewska A; Bilińska-Nigot B; Ostrowski K; Semenicki K
    Neurol Neurochir Pol; 1978; 12(4):387-96. PubMed ID: 714218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double-blind crossoer clinical trial of pyridinolcarbamate in peripheral arterial disease (arteriosclerosis obliterans).
    Walton KW; Craig GM; Prior P; Waterhouse JA; Skilton J
    Br Heart J; 1973 Feb; 35(2):211-9. PubMed ID: 4570447
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical and laboratory examinations with Prodectin.
    Bédi J; Kosztovics A; Pálos LA
    Ther Hung; 1976; 24(3):91-7. PubMed ID: 1013926
    [No Abstract]   [Full Text] [Related]  

  • 12. [Prodectin treatment of partial hearing loss as a result of atherosclerosis].
    Smirnova NA; Timakov VA; Mikushkin MK
    Vestn Otorinolaringol; 1982; (6):53-6. PubMed ID: 7179649
    [No Abstract]   [Full Text] [Related]  

  • 13. [The pyridinolcarbamate-clofibrate combination in the treatment of vascular diseases in diabetics].
    Parodi FA; Caputo G
    Clin Ter; 1976 Dec; 79(6):571-81. PubMed ID: 1009761
    [No Abstract]   [Full Text] [Related]  

  • 14. [Effect of pyridinol carbamate (Anginin) in peripheral arterial blood circulation disorders].
    Heisig N; Westermann KW; Stolterfoht CA; Zaki J
    Med Klin; 1970 Dec; 65(52):2289-93. PubMed ID: 5522670
    [No Abstract]   [Full Text] [Related]  

  • 15. Antiatherogenic effect of pyridinolcarbamate (prodectin). Experimental study.
    Orbetzova V; Jurukova Z; Orbetzova M
    Artery; 1980; 8(6):560-9. PubMed ID: 7259535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Use of prodectin in pulmonary tuberculosis].
    Safarov RN; Makinskiĭ AI
    Vrach Delo; 1981 Nov; (11):83-4. PubMed ID: 7342450
    [No Abstract]   [Full Text] [Related]  

  • 17. [The importance of pyridinolcarbamate and clofibrate association in the treatment of arteriosclerosis].
    Pola P
    Minerva Cardioangiol; 1975 Apr; 23(4):261-9. PubMed ID: 1095958
    [No Abstract]   [Full Text] [Related]  

  • 18. [The importance of pyridinolcarbamate and clofibrate association in the treatment of arteriosclerosis].
    Pola P
    J Pharm Sci; 1975 Jan; 64(1):261-9. PubMed ID: 1094102
    [No Abstract]   [Full Text] [Related]  

  • 19. [Therapeutic results with combination of pyridinolcarbamate and clofibrate in atherosclerotic patients].
    Valiensi M; Riboli E; Lombardi M
    Minerva Cardioangiol; 1976 Feb; 24(2):148-54. PubMed ID: 1256654
    [No Abstract]   [Full Text] [Related]  

  • 20. [Use of the antikinin preparation prodectin in the complex treatment of pulmonary tuberculosis patients].
    Keleberda KIa; Svistunova AS; Kaminskaia GO; Kordonskaia VM
    Probl Tuberk; 1982 Oct; (10):42-5. PubMed ID: 7178102
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.